Livzon Pharma Announces Updated Board and Committee Line-up

Bulletin Express
11/12

Livzon Pharmaceutical Group Inc. (Livzon Pharma) has released an updated roster of its Board of Directors and the corresponding committee assignments, effective 12 November 2026 from headquarters in Zhuhai, China.

The Board now comprises nine members: • Executive Directors – Chairman and President Liu Daping; Vice Chairman Tang Yanggang • Non-executive Directors – Lin Nanqi, Qiu Qingfeng, Zhu Linlin • Employee Representative Director – Ran Yongmei • Independent Non-executive Directors – Luo Huiyuan, Cui Lijie, Wang Zhiyao, Kang Li

Five board committees remain in place, with leadership and membership as follows: 1. Audit Committee: Chaired by Independent Non-executive Director Luo Huiyuan, with Kang Li, Cui Lijie, and Wang Zhiyao serving as members. 2. Remuneration and Assessment Committee: Chaired by Independent Non-executive Director Cui Lijie; Tang Yanggang, Kang Li, and Ran Yongmei are members. 3. Nomination Committee: Independent Non-executive Director Kang Li takes the chair; Tang Yanggang, Cui Lijie, and Ran Yongmei serve as members. 4. Strategy Committee: Chairman Liu Daping heads the committee, joined by Tang Yanggang and Cui Lijie as members. 5. Environmental, Social and Governance Committee: Chaired by Liu Daping, with Tang Yanggang and Kang Li as members.

These appointments reinforce Livzon Pharma’s governance framework by balancing executive leadership with independent oversight and specialized committee expertise.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10